SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
|Date of report (Date of earliest event reported)||July 31, 2019|
|(Exact Name of Registrant as Specified in Its Charter)|
|(State or Other Jurisdiction of Incorporation)||(Commission File Number)||(I.R.S. Employer Identification No.)|
1 Controls Drive,
|(Address of Principal Executive Offices)||(Zip Code)|
|(Registrant's Telephone Number, Including Area Code)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class:||Trading Symbol(s)||Name of each exchange on which registered:|
|Item 5.02.||Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
Effective July 31, 2019, Dr. Mukund Kulkarni resigned as a Member of the Board of Directors of NanoViricides, Inc. (the “Company”) as well as a Member of its Audit, Nominating and Compensation Committees. Dr. Kulkarni resigned for personal reasons and did not indicate that his decision to resign was a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. A copy of the letter received from Dr. Kulkarni regarding his resignation is attached to this Current Report of Form 8-K as Exhibit 17.1.
|Item 9.01.||Financial Statements and Exhibits.|
|17.1||Letter from Dr. Mukund Kulkarni|
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.
|Date: August 1, 2019||By:||/s/ Anil Diwan|
Name: Anil Diwan
Title: Chairman, President
|Mukund Kulkarni, PhD, MBA||July 31, 2019|
Anil R. Diwan
Chairman of the Board
I have previously expressed my desire to retire from the Board of Directors of NanoViricides. Inc. to you and the other Board members due to health reasons. Now that a new member of the Board of Directors has been appointed, please consider this as my official resignation from the Board of Directors of NanoViricides, Inc. effective immediately.
Please be assured that I do not have any disagreements with the Company’s Management team on any matter including but not limited to the Company’s operations, policies or practices. I believe that the Company has always been run in the best interests of its shareholders.
It has been my pleasure to serve on the Board with such esteemed colleagues. I believe that the Company has made great strides towards taking its technology from the lab into the clinic, despite limited funding and other resource limitations compared to other bio-pharma companies. It has concurrently increased the depth and breadth of its fundamental capabilities to ensure a successful launch of its product platform. I believe that the Company has a great future.
|/s/ Mukund Kulkarni|